WO2010025016A3 - Enhancement of transgene expression from virus-based vaccine vectors using suppressors of the type 1 interferon response - Google Patents

Enhancement of transgene expression from virus-based vaccine vectors using suppressors of the type 1 interferon response Download PDF

Info

Publication number
WO2010025016A3
WO2010025016A3 PCT/US2009/052969 US2009052969W WO2010025016A3 WO 2010025016 A3 WO2010025016 A3 WO 2010025016A3 US 2009052969 W US2009052969 W US 2009052969W WO 2010025016 A3 WO2010025016 A3 WO 2010025016A3
Authority
WO
WIPO (PCT)
Prior art keywords
type
mammalian host
proteins
interfere
host cell
Prior art date
Application number
PCT/US2009/052969
Other languages
French (fr)
Other versions
WO2010025016A2 (en
Inventor
Jerald C. Sadoff
John Fulkerson
Michele Stone
Original Assignee
Aeras Global Tb Vaccine Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeras Global Tb Vaccine Foundation filed Critical Aeras Global Tb Vaccine Foundation
Publication of WO2010025016A2 publication Critical patent/WO2010025016A2/en
Publication of WO2010025016A3 publication Critical patent/WO2010025016A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Abstract

Baculovirus vectors with improved ability to express transgenes are provided. The baculovirus vectors are genetically engineered to contain and express nucleic acid sequences that encode one or more proteins that interfere with mammalian host cell type I interferon (IFN) responses. Thus, the expression of transgenes encoded by the baculovirus vector is not inhibited by a type I DFN response, and the transgenes are freely expressed in mammalian host cells. Alternatively, baculovirus vectors with nucleotide sequences encoding one or more genes of interest (e.g. tuberculosis or malarial antigens) are co-administered with one or more proteins that interfere with mammalian host cell type I IFN responses; or with viral vectors (e.g. adenovectors) that express one or more proteins that interfere with mammalian host cell type I IFN responses.
PCT/US2009/052969 2008-08-06 2009-08-06 Enhancement of transgene expression from virus-based vaccine vectors using suppressors of the type 1 interferon response WO2010025016A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8652308P 2008-08-06 2008-08-06
US61/086,523 2008-08-06

Publications (2)

Publication Number Publication Date
WO2010025016A2 WO2010025016A2 (en) 2010-03-04
WO2010025016A3 true WO2010025016A3 (en) 2010-05-14

Family

ID=41722208

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/052969 WO2010025016A2 (en) 2008-08-06 2009-08-06 Enhancement of transgene expression from virus-based vaccine vectors using suppressors of the type 1 interferon response

Country Status (1)

Country Link
WO (1) WO2010025016A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114957489B (en) * 2022-06-20 2023-11-21 甘肃省畜牧兽医研究所 Porcine rotavirus recombinant protein and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287129A1 (en) * 2004-05-18 2005-12-29 Cicciarelli James C Vectors and methods for long-term immune evasion to prolong transplant viability
WO2009036137A1 (en) * 2007-09-12 2009-03-19 Aeras Global Tb Vaccine Foundation Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type i interferon response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050287129A1 (en) * 2004-05-18 2005-12-29 Cicciarelli James C Vectors and methods for long-term immune evasion to prolong transplant viability
WO2009036137A1 (en) * 2007-09-12 2009-03-19 Aeras Global Tb Vaccine Foundation Methods to increase transgene expression from bacterial-based delivery systems by co-expressing suppressors of the eukaryotic type i interferon response

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ABE, T. ET AL.: "Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice", J IMMUNOL., vol. 171, no. 3, 2003, pages 1133 - 1139 *
ABE, T. ET AL.: "Baculovirus induces Type I interferon production through Toll-Like receptor-dependent and - independent pathways in a cell-type-specific manner", J VIROL., vol. 83, no. 15, 27 May 2009 (2009-05-27), pages 7629 - 7640 *
BARRO, M. ET AL.: "Rotavirus nonstructural protein 1 subverts innate immune response by inducing degradation of IFN regulatory factor 3", PROC NATL ACD SCI USA, vol. 102, no. 11, 15 March 2005 (2005-03-15), pages 4114 - 4119 *
HAVLIR, D.V. ET AL.: "Human Immune Response to Mycobacterium tuberculosis Antigens", INFECTION AND IMMUNITY, vol. 59, no. 2, February 1991 (1991-02-01), pages 665 - 670 *
LEE, HP. ET AL.: "Baculovirus transduction of chondrocytes elicits interferon- alpha/beta and suppresses transgene expression", J GENE MEDICINE, vol. 11, 4 February 2009 (2009-02-04), pages 302 - 312 *
ZALDUMBIDE, A. ET AL.: "How not to be seen: immune-evasion strategies in gene therapy", GENE THERAPY, vol. 15, 29 November 2007 (2007-11-29), pages 239 - 246 *

Also Published As

Publication number Publication date
WO2010025016A2 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
WO2011033375A3 (en) Products and methods for enhanced transgene expression and processing
WO2006127956A3 (en) Rapid production of adenovirus-free recombinant adenovirus vectors
WO2006012221A3 (en) Target cell-specific short interfering rna and methods of use thereof
JP2013507935A5 (en)
WO2007027860A3 (en) Adenoviral vector-based malaria vaccines
NZ593598A (en) Optimized antiviral vaccines with improved cellular immunogenicity
CA2860388C (en) Parainfluenza virus 5 based vaccines
DK1760153T3 (en) Adenovirus / alphavirus hybrid vector for efficient administration and expression of therapeutic genes in tumor cells
WO2010105251A3 (en) Non-integrating retroviral vector vaccines
JP2011530309A5 (en)
MXPA02006888A (en) Recombinant flaviviruses and methods of use thereof.
WO2009117116A3 (en) Heat shock protein gp96 vaccination and methods of using same
WO2006096989A3 (en) Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the gly-gly-ala domain for enhanced transient gene expression
JP2010538649A5 (en)
MX2013010794A (en) Rapid and prolonged immunologic-therapeutic.
WO2006008468A3 (en) Adenovirus vector and method to manipulate the adenovirus genome
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
MX2009012597A (en) Raccoon poxvirus expressing rabies glycoproteins.
NZ598605A (en) Vaccine against african horse sickness virus
WO2010025016A3 (en) Enhancement of transgene expression from virus-based vaccine vectors using suppressors of the type 1 interferon response
NZ591439A (en) pCAGGS VECTOR COMPRISING AN 829 BASE PAIR DELETION IN THE CHICKEN-BETA ACTIN INTRON WHICH RESULTS IN ENHANCED EXPRESSION OF A GENE OF INTEREST
WO2013052814A8 (en) E1 enzyme mutants and uses thereof
WO2013032999A3 (en) Polydnavirus vectors
WO2009079606A3 (en) Microrna-induced es-like cells and uses thereof
MX2010010025A (en) Fusion protein that directs vaccine antigens to antigen-presenting cells, and applications thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09810431

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09810431

Country of ref document: EP

Kind code of ref document: A2